GenMark Diagnostics (GNMK) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
- Twilio, Vylor set to join S&P 500 as index reshuffles members
GenMark Diagnostics (GNMK) Announces Another ePlex Delay; Canaccord Genuity Cuts Price Target to $8
October 28, 2015 11:02 AM EDTCanaccord Genuity maintained a Buy rating on GenMark Diagnostics (NASDAQ: GNMK), and cut the price target to $8.00 (from $14.00), following the announcement of another delay on ePlex. GNMK cited their need to redesign plastic-injected parts to 2 components of their cartridge. GNMK pushed out its timelines by another quarter,... More
GenMark Diagnostics (GNMK) Pushes ePlex Launch to 2016; Needham & Company Cuts Price Target to $13
October 28, 2015 7:11 AM EDTNeedham & Company maintained a Buy rating on GenMark Diagnostics (NASDAQ: GNMK), and cut the price target to $13.00 (from $16.00), following the company's 3Q15 earnings results. Revenue was $8.5M vs. consensus of $8.2M and GAAP EPS was ($0.27) vs. consensus of ($0.31). Management now believes that the launch of the sample-to-answer... More
